Matrix metalloproteinase inhibitors 1998

Inhibition of matrix metalloproteinases (MMPs) as an approach to treatment of diseases such as cancer, arthritis and multiple sclerosis (MS) is now an area of intense interest within the pharmaceutical industry. This review summarises developments in the design and clinical evaluation of synthetic MMP inhibitors since the subject was last covered in this journal in 1996.

[1]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[2]  T. Oikawa,et al.  Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. , 1995, Chemical & pharmaceutical bulletin.

[3]  H. V. Van Wart,et al.  Synthetic inhibitors of bacterial and mammalian interstitial collagenases. , 1992, Progress in medicinal chemistry.

[4]  M. Whittaker,et al.  A method for the synthesis of hydroxamic acids on solid phase , 1996 .

[5]  K. D. Hardman,et al.  Potent carboxylate inhibitors of stromelysin containing P2′ piperazic acids and P1′ biaryl moeities , 1997 .

[6]  W. Chan,et al.  N-Fmoc-aminooxy-2-chlorotrityl polystyrene resin: A facile solid-phase methodology for the synthesis of hydroxamic acids☆ , 1997 .

[7]  D. J. Nelson,et al.  Amide surrogates of matrix metalloproteinase inhibitors : Urea and sulfonamide mimics , 1997 .

[8]  J. Bermak,et al.  A Transition State Analog Inhibitor Combinatorial Library , 1995 .

[9]  S. Hammond,et al.  Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostere ☆ , 1996 .

[10]  J. Bishop,et al.  Ro 32‐3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo , 1997, British journal of pharmacology.

[11]  M. Desai,et al.  A TFA-CLEAVABLE LINKAGE FOR SOLID-PHASE SYNTHESIS OF HYDROXAMIC ACIDS , 1997 .

[12]  N. Yates,et al.  Solid-phase synthesis of a N-carboxyalkyl tripeptide combinatorial library , 1997 .

[13]  S. Bramhall.  The matrix metalloproteinases and their inhibitors in pancreatic cancer , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[14]  K. Tanzawa,et al.  Isolation of nicotianamine as a gelatinase inhibitor. , 1996, The Journal of antibiotics.

[15]  Stephen Hanessian,et al.  Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinases , 1997 .

[16]  R. Mayer,et al.  Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing. , 1998, Bioorganic & medicinal chemistry letters.

[17]  W. Bode,et al.  Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. , 1995, Biochemistry.

[18]  Y. Obata,et al.  Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors. , 1997, Bioorganic & medicinal chemistry.

[19]  N. Borkakoti,et al.  Collagenase inhibitors: their design and potential therapeutic use. , 1987, Journal of enzyme inhibition.

[20]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[21]  K. D. Hardman,et al.  Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases. , 1998, Bioorganic & medicinal chemistry letters.

[22]  A. Spatola,et al.  Solid phase synthesis of peptide hydroxamic acids , 1997 .

[23]  J. Cossins,et al.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.

[24]  Davidr . Evans,et al.  C2-SYMMETRIC COPPER(II) COMPLEXES AS CHIRAL LEWIS ACIDS. CATALYTIC ENANTIOSELECTIVE ALDOL ADDITIONS OF ENOLSILANES TO PYRUVATE ESTERS , 1997 .

[25]  D. Patel,et al.  A New and Efficient Solid Phase Synthesis of Hydroxamic Acids. , 1997, The Journal of organic chemistry.

[26]  J. Laydon,et al.  Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing , 1997, Inflammation Research.

[27]  D. Wilson,et al.  Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. , 1997, Journal of medicinal chemistry.

[28]  X. Zhang,et al.  Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. , 1997, Bioorganic & medicinal chemistry.

[29]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[30]  S. Liras,et al.  Cyclopropanes as conformationally restricted peptide isosteres. Design and synthesis of novel collagenase inhibitors , 1993 .

[31]  A. H. Drummond,et al.  Recent advances in matrix metalloproteinase inhibitor research , 1996 .

[32]  J. Schullek,et al.  A high-density screening format for encoded combinatorial libraries: assay miniaturization and its application to enzymatic reactions. , 1997, Analytical biochemistry.

[33]  N. Borkakoti,et al.  Design and synthesis of the cartilage protective agent (CPA, Ro32-3555) , 1997 .

[34]  T. Cawston.  Metalloproteinase inhibitors and the prevention of connective tissue breakdown. , 1996, Pharmacology & therapeutics.

[35]  D. Manallack,et al.  Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety , 1997 .

[36]  B. Pfeiffer,et al.  Asymmetric synthesis of a conformationally constrained N-phosphonoalkyl dipeptide , 1997 .

[37]  J. Montana,et al.  A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders , 1997 .

[38]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[39]  M. Maccoss,et al.  Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. , 1997, Journal of medicinal chemistry.

[40]  A. H. Drummond,et al.  Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket , 1997 .

[41]  A. Koskinen,et al.  A NOVEL LINKAGE FOR THE SOLID-PHASE SYNTHESIS OF HYDROXAMIC ACIDS , 1997 .

[42]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[43]  N. Borkakoti,et al.  Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor , 1994, Nature Structural Biology.

[44]  D. Talbot,et al.  Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. , 1996, European journal of cancer.

[45]  M. Lambert,et al.  Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistry , 1996 .

[46]  A. H. Drummond,et al.  Processing of tumour necrosis factor-α precursor by metalloproteinases , 1994, Nature.

[47]  E. Gordon,et al.  A general and efficient solid phase synthesis of quinazoline-2,4-diones , 1997 .

[48]  R. Wahl,et al.  A Metalloproteinase Inhibitor from Doliocarpus verruculosus , 1996 .

[49]  R. Bast,et al.  Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.

[50]  M. Gore,et al.  Tumour marker levels during marimastat therapy , 1996, The Lancet.

[51]  W. DeGrado,et al.  Complementarity of Combinatorial Chemistry and Structure-Based Ligand Design: Application to the Discovery of Novel Inhibitors of Matrix Metalloproteinases , 1996 .

[52]  R. Beckett.  Patent Update Oncologic, Endocrine & Metabolic: Oncologic, Endocrine & Metabolic: Recent advances in the field of matrix metalloproteinase inhibitors , 1996 .

[53]  Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the succinamide hydroxamate series , 1996 .

[54]  J. W. Becker,et al.  Chapter 24. Inhibition of Matrix Metalloproteinases. , 1996 .

[55]  Y. Kitade,et al.  Inhibitory effect on HT-1080 tumor cell invasion in vitro using 9-(2′-hydroxyethyl)adenine 2′-phosphates , 1998 .

[56]  A. D. White,et al.  Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase Inhibitors , 1997, Current Pharmaceutical Design.

[57]  Jean M. Severin,et al.  Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .

[58]  A. H. Drummond,et al.  The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement. , 1998, Bioorganic & medicinal chemistry letters.